RIGEL PHARMACEUTICALS INC — Investor Relations & Filings
Filings indexed
1,024
across all filing types
Latest filing
2024-11-27
Director's Dealing
Country
US
United States of America
Listing
US
RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and provides novel small-molecule drugs. The company focuses on therapies for hematologic disorders, cancer, and rare immune diseases. Its portfolio of commercialized products includes TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia, REZLIDHIA® (olutasidenib) for relapsed or refractory acute myeloid leukemia, and GAVRETO® (pralsetinib). In addition to its commercial products, Rigel maintains a clinical development pipeline investigating therapies such as IRAK1/4 and RIPK1 inhibitors for various inflammatory and immune conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Director's Dealing 2024 | 2024-11-27 | English | |
| Major Shareholding Notification 2024 | 2024-11-14 | English | |
| AMENDMENT NO. 2 TO SCHEDULE 13G | 2024-11-14 | English | |
| FORM 8-K | 2024-11-07 | English | |
| 10-Q | 2024-11-07 | English | |
| FORM 8-K | 2024-09-19 | English |
Browse filings by year
21 years- 2026 24 filings
- 2025 63 filings
- 2024 58 filings
- 2023 41 filings
- 2022 55 filings
- 2021 51 filings
- 2020 43 filings
- 2019 63 filings
- 2018 67 filings
- 2017 58 filings
- 2016 51 filings
- 2015 46 filings
- 2014 42 filings
- 2013 45 filings
- 2012 54 filings
- 2011 41 filings
- 2010 50 filings
- 2009 55 filings
- 2008 39 filings
- 2007 55 filings
- 2006 23 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 10862294 | Director's Dealing 2024 | 2024-11-27 | English | ||
| 10862295 | Major Shareholding Notification 2024 | 2024-11-14 | English | ||
| 10862296 | AMENDMENT NO. 2 TO SCHEDULE 13G | 2024-11-14 | English | ||
| 10862297 | FORM 8-K | 2024-11-07 | English | ||
| 10862298 | 10-Q | 2024-11-07 | English | ||
| 10862299 | FORM 8-K | 2024-09-19 | English | ||
| 10862300 | Director's Dealing 2024 | 2024-09-05 | English | ||
| 10862301 | Director's Dealing 2024 | 2024-09-05 | English | ||
| 10862302 | FORM 8-K | 2024-09-03 | English | ||
| 10862303 | Regulatory Filings 2024 | 2024-08-12 | English | ||
| 10862304 | Regulatory Filings 2024 | 2024-08-08 | English | ||
| 10862305 | Regulatory Filings 2024 | 2024-08-07 | English | ||
| 10862306 | S-8 | 2024-08-06 | English | ||
| 10862307 | FORM 8-K | 2024-08-06 | English | ||
| 10862308 | 10-Q | 2024-08-06 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
RIGEL PHARMACEUTICALS INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32801/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32801 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32801 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32801 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32801}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for RIGEL PHARMACEUTICALS INC (id: 32801)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.